OTCMKTS:DGNOF DIAGNOS (DGNOF) Stock Price, News & Analysis $0.25 +0.01 (+5.38%) As of 02:56 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About DIAGNOS Stock (OTCMKTS:DGNOF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DIAGNOS alerts:Sign Up Key Stats Today's Range$0.25▼$0.2650-Day Range$0.24▼$0.3652-Week Range$0.13▼$0.38Volume52,490 shsAverage Volume102,896 shsMarket Capitalization$31.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview DIAGNOS Inc. is a Canadian healthcare technology company that develops artificial intelligence and data-analysis solutions for the early detection of diseases. Its principal platform, CARA, is designed to analyze retinal images and assist healthcare professionals in screening for diabetic retinopathy and other eye-related conditions. The company’s technology is intended to support screening programs in settings such as primary-care offices, pharmacies, clinics and community health facilities. By combining retinal imaging with automated analysis, DIAGNOS seeks to expand access to screening and help identify patients who may require further examination by an eye-care professional. Founded in 1998 and headquartered in Brossard, Quebec, DIAGNOS has pursued collaborations and deployments with healthcare organizations in Canada and other international markets. The company has also historically been involved in mineral exploration, but its business focus has centered increasingly on healthcare-related artificial intelligence and diagnostic services.AI Generated. May Contain Errors. Read More Receive DGNOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DIAGNOS and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DGNOF Stock News HeadlinesDIAGNOS Advances Regulatory Strategy with US FDA Submission for CARA SystemSeptember 28, 2026 | globenewswire.comDIAGNOS to Hold its Annual General Meeting of Shareholders on September 30, 2026September 14, 2026 | globenewswire.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 2 at 1:00 AM | Behind the Markets (Ad)DIAGNOS Receives Saudi FDA Medical Device License for CARA System, Bringing AI-Assisted Retinal Image Analysis to Saudi ArabiaAugust 13, 2026 | globenewswire.comDIAGNOS Receives Health Canada Medical Device Licence for CARA System, Bringing AI-Assisted Retinal Image Analysis to Canadian OptometristsJuly 27, 2026 | globenewswire.comEmerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI PlatformJune 5, 2026 | globenewswire.comDIAGNOS to Present at the Emerging Growth Conference on June 10, 2026June 3, 2026 | globenewswire.comDIAGNOS Announces Amendment to Convertible DebenturesMay 13, 2026 | globenewswire.comSee More Headlines DGNOF Stock Analysis - Frequently Asked Questions How have DGNOF shares performed this year? DIAGNOS's stock was trading at $0.2647 at the start of the year. Since then, DGNOF shares have decreased by 6.0% and is now trading at $0.2489. How were DIAGNOS's earnings last quarter? DIAGNOS Inc. (OTCMKTS:DGNOF) released its quarterly earnings data on Thursday, June, 11th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of ($0.01) by $0.00. The business had revenue of $10 thousand for the quarter, compared to analysts' expectations of $47 thousand. How do I buy shares of DIAGNOS? Shares of DGNOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings6/11/2026Today11/02/2026Next Earnings (Estimated)11/02/2026Fiscal Year End3/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Technology Sub-IndustryHealthcare Technology Current SymbolOTCMKTS:DGNOF CIK1790693 Webwww.diagnos.ca Phone(450) 678-8882FaxN/AEmployees22Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.30 million Net Margins-7,014.89% Pretax Margin-6,956.72% Return on EquityN/A Return on Assets-192.10% Debt Debt-to-Equity Ratio0.33 Current Ratio1.49 Quick Ratio1.49 Sales & Book Value Annual Sales$50 thousand Price / Sales622.75 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares125,100,000Free FloatN/AMarket Cap$31.14 million OptionableNot Optionable Beta0.05 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (OTCMKTS:DGNOF) was last updated on 11/2/2026 by MarketBeat.com Staff. From Our PartnersTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredThe most dangerous moment in a financial crisisDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredDollar Reset – Are You Prepared?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredThe midterm election trade Wall Street isn't talking aboutWhitney Tilson, known as The Prophet by CNBC, believes the 2026 midterm elections could become a major market ...Stansberry Research | SponsoredNvidia's $550 Trillion ProblemDo not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DIAGNOS Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DIAGNOS With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
